Simeon George
CIK 1595117 · last filed 2026-10-16
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ACLX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
929 MAIN STREET, SUITE 200
REDWOOD CITY, CA 94063
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CRSP | Director | 85,173 | $51.47 | $4.38M | $50.78M | 12 | 2026-10-16 |
| ADRX | Director | 1,953,505 | — | — | $27.20M | 1 | 2026-09-29 |
| NKTX | Director | 666,667 | $1.70 | $1.13M | $40.00M | 9 | 2026-06-11 |
| DSGN | Director | 6,486,476 | $10.63 | $68.95M | $12.57M | 8 | 2026-06-11 |
| ODTX | 10%+ Owner | 734,868 | $19.50 | $14.33M | $19.94M | 1 | 2026-05-11 |
| AVLN | 10%+ Owner | 1,419,298 | $25.83 | $36.66M | $20.00M | 1 | 2026-05-01 |
| ZBIO | 10%+ Owner | 669,061 | $27.30 | $18.27M | $76.00M | 1 | 2024-09-16 |
| Turning Point Therapeutics, Inc. (TPTX) Delisted | Director | 0 | $76.01 | $0 | $18.85M | 6 | 2022-08-17 |
| Arcellx, Inc. (ACLX) Delisted | 10%+ Owner | 2,216,960 | $115.07 | $255.11M | $150.00M | 1 | 2022-02-10 |
| Principia Biopharma Inc. (PRNB) Delisted | Director | 0 | — | — | $14.59M | 6 | 2020-09-28 |
| CRISPR Therapeutics AG (PZRX) Delisted | Director | 3,220,627 | — | — | $931.0K | 3 | 2017-06-02 |
| GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | Director | 114,933 | $0.00 | $69 | $1.73M | 1 | 2014-02-11 |
Recent Filings · Page 4 of 6
51 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-06-04 | Turning Point Therapeutics, Inc. (TPTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-04-01 | DSGN | Mixed | +5,626,476 | $5.00M | EDGAR |
| 2021-03-29 | DSGN | Grant (A) | — | $0 | EDGAR |
| 2020-09-28 | Principia Biopharma Inc. (PRNB) Delisted | Mixed | −2,982,855 | -$298.29M | EDGAR |
| 2020-07-13 | NKTX | Grant (A) | — | $0 | EDGAR |
| 2020-06-17 | Turning Point Therapeutics, Inc. (TPTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-06-15 | CRSP | Grant (A) | — | $0 | EDGAR |
| 2020-06-08 | Principia Biopharma Inc. (PRNB) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-05-26 | Turning Point Therapeutics, Inc. (TPTX) Delisted | Buy (P) | +83,333 | $5.00M | EDGAR |
| 2019-10-22 | Principia Biopharma Inc. (PRNB) Delisted | Buy (P) | +357,142 | $10.00M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.